Bionomics (ASX: BNO) is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system (CNS).  Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a compound that potently and selectively restricts blood flow within tumours.

BNC210

A clinical program is underway for the treatment of anxiety disorders and depression based on BNC210, a compound which stimulates neurite outgrowth. BNC210 is partnered with Ironwood Pharmaceuticals. Bionomics has a partnered program with Merck Serono for new treatments for multiple sclerosis. 

Technology Platforms

Bionomics' discovery and development activities are driven by its three technology platforms:

Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels).

MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs.

ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

These platforms underpin Bionomics’ established business strategy and Bionomics is committed to securing partners for its key compounds. +

Product Pipeline